Synergistic oligodeoxynucleotide strongly promotes CpG-induced interleukin-6 production

BMC Immunology Volume 18 Page 44- published_at 2017-10-04
アクセス数 : 688
ダウンロード数 : 58

今月のアクセス数 : 1
今月のダウンロード数 : 1
File
bmci_18_44.pdf 1.1 MB 種類 : fulltext
Title ( eng )
Synergistic oligodeoxynucleotide strongly promotes CpG-induced interleukin-6 production
Creator
Nigar Shireen
Okajima Takuma
Shigemori Suguru
Sato Takashi
Ogita Tasuku
Shimosato Takeshi
Source Title
BMC Immunology
Volume 18
Start Page 44
Abstract
[Background] :Bacterial genomes span a significant portion of diversity, reflecting their adaptation strategies; these strategies include nucleotide usage biases that affect chromosome configuration. Here, we explore an immuno-synergistic oligodeoxynucleotide (iSN-ODN, named iSN34), derived from Lactobacillus rhamnosusGG (LGG) genomic sequences, that exhibits a synergistic effect on immune response to CpG-induced immune activation.
[Methods]: The sequence of iSN34 was designed based on the genomic sequences of LGG. Pathogen-free mice were purchased from Japan SLC and maintained under temperature- and light-controlled conditions. We tested the effects of iSN34 exposure in vitro and in vivo by assessing effects on mRNA expression, protein levels, and cell type in murine splenocytes.
[Results]: We demonstrate that iSN34 has a significant stimulatory effect when administered in combination with CpGODN, yielding enhanced interleukin (IL)-6 expression and production. IL-6 is a pleotropic cytokine that has been shown to prevent epithelial apoptosis during prolonged inflammation.
[Conclusions]: Our results are the first report of a bacterial-DNA-derived ODN that exhibits immune synergistic activity.The potent over-expression of IL-6 in response to treatment with the combination of CpG ODN and iSN34 suggests anew approach to immune therapy.This finding may lead to novel clinical strategies for the prevention or treatment of dysfunctions of the innate and adaptive immune systems.
Keywords
LGG
CpG-ODN
iSN-ODN
IL-6
Synergistic effect
Descriptions
This work was supported by A-STEP (Adaptable and Seamless Technology Transfer Program through Target-driven R&D).
Language
eng
Resource Type journal article
Publisher
BioMed Central Ltd
Date of Issued 2017-10-04
Rights
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Publish Type Version of Record
Access Rights open access
Source Identifier
[DOI] 10.1186/s12865-017-0227-7
[PMID] 28978323
[ISSN] 1471-2172
[DOI] https://doi.org/10.1186/s12865-017-0227-7